Terms: = Bone cancer AND IDH2, P48735, 3418, ENSG00000182054, IDHM, mNADP-IDH, IDH, IDP, ICD-M
213 results:
1. A personalized medicine approach identifies enasidenib as an efficient treatment for idh2 mutant chondrosarcoma.
Rey V; Tornín J; Alba-Linares JJ; Robledo C; Murillo D; Rodríguez A; Gallego B; Huergo C; Viera C; Braña A; Astudillo A; Heymann D; Szuhai K; Bovée JVMG; Fernández AF; Fraga MF; Alonso J; Rodríguez R
EBioMedicine; 2024 Apr; 102():105090. PubMed ID: 38547578
[TBL] [Abstract] [Full Text] [Related]
2. Treatment with the apoptosis inhibitor Asunercept reduces clone sizes in patients with lower risk Myelodysplastic Neoplasms.
Streuer A; Jann JC; Boch T; Mossner M; Riabov V; Schmitt N; Altrock E; Xu Q; Demmerle M; Nowak V; Oblaender J; Palme I; Weimer N; Rapp F; Metzgeroth G; Hecht A; Höger T; Merz C; Hofmann WK; Nolte F; Nowak D
Ann Hematol; 2024 Apr; 103(4):1221-1233. PubMed ID: 38413410
[TBL] [Abstract] [Full Text] [Related]
3. Characterizing Immune Infiltration in Esthesioneuroblastoma Subtypes Through Gene Expression Deconvolution.
Batchu S; Gill AS; Karsy M
World Neurosurg; 2024 Mar; 183():e928-e935. PubMed ID: 38246527
[TBL] [Abstract] [Full Text] [Related]
4. Mitochondrial isocitrate dehydrogenase impedes CAR T cell function by restraining antioxidant metabolism and histone acetylation.
Si X; Shao M; Teng X; Huang Y; Meng Y; Wu L; Wei J; Liu L; Gu T; Song J; Jing R; Zhai X; Guo X; Kong D; Wang X; Cai B; Shen Y; Zhang Z; Wang D; Hu Y; Qian P; Xiao G; Huang H
Cell Metab; 2024 Jan; 36(1):176-192.e10. PubMed ID: 38171332
[TBL] [Abstract] [Full Text] [Related]
5. Tumor heterogeneity and tumor-microglia interactions in primary and recurrent idh1-mutant gliomas.
Blanco-Carmona E; Narayanan A; Hernandez I; Nieto JC; Elosua-Bayes M; Sun X; Schmidt C; Pamir N; Özduman K; Herold-Mende C; Pagani F; Cominelli M; Taranda J; Wick W; von Deimling A; Poliani PL; Rehli M; Schlesner M; Heyn H; Turcan Ş
Cell Rep Med; 2023 Nov; 4(11):101249. PubMed ID: 37883975
[TBL] [Abstract] [Full Text] [Related]
6. [TFH lymphoma and associated clonal hematopoiesis].
Nann D; Fend F; Quintanilla-Martinez L
Pathologie (Heidelb); 2023 Dec; 44(Suppl 3):144-149. PubMed ID: 37870568
[TBL] [Abstract] [Full Text] [Related]
7. Immune Surveillance of Acute Myeloid Leukemia Is Mediated by HLA-Presented Antigens on Leukemia Progenitor Cells.
Nelde A; Schuster H; Heitmann JS; Bauer J; Maringer Y; Zwick M; Volkmer JP; Chen JY; Stanger AMP; Lehmann A; Appiah B; Märklin M; Rücker-Braun E; Salih HR; Roerden M; Schroeder SM; Häring MF; Schlosser A; Schetelig J; Schmitz M; Boerries M; Köhler N; Lengerke C; Majeti R; Weissman IL; Rammensee HG; Walz JS
Blood Cancer Discov; 2023 Nov; 4(6):468-489. PubMed ID: 37847741
[TBL] [Abstract] [Full Text] [Related]
8. Targeted single-cell RNA sequencing analysis reveals metabolic reprogramming and the ferroptosis-resistant state in hematologic malignancies.
Shen X; Dong P; Kong J; Sun N; Wang F; Sang L; Xu Y; Zhang M; Chen X; Guo R; Wang S; Lin Q; Jiang Z; Xu S; Zhang C; Bian Z; Wang W; Guo R
Cell Biochem Funct; 2023 Dec; 41(8):1343-1356. PubMed ID: 37823726
[TBL] [Abstract] [Full Text] [Related]
9. idh mutations in G2-3 conventional central bone chondrosarcoma: a mono institutional experience.
Setola E; Benini S; Righi A; Gamberi G; Carretta E; Ferrari C; Avnet S; Palmerini E; Magagnoli G; Gambarotti M; Lollini PL; Cesari M; Cocchi S; Paioli A; Longhi A; Scotlandi K; Laginestra MA; Donati DM; Baldini N; Ibrahim T
BMC Cancer; 2023 Sep; 23(1):907. PubMed ID: 37752419
[TBL] [Abstract] [Full Text] [Related]
10. Clinico-Genomic Profiling of Conventional and Dedifferentiated Chondrosarcomas Reveals TP53 Mutation to Be Associated with Worse Outcomes.
Denu RA; Yang RK; Lazar AJ; Patel SS; Lewis VO; Roszik J; Livingston JA; Wang WL; Shaw KR; Ratan R; Zarzour MA; Bird J; Raza S; Akdemir KC; Rodon Ahnert J; Subbiah V; Patel S; Conley AP
Clin Cancer Res; 2023 Dec; 29(23):4844-4852. PubMed ID: 37747813
[TBL] [Abstract] [Full Text] [Related]
11. idh-negative chondrosarcoma with metachronous dedifferentiation only in the metastatic site-A diagnostic pitfall.
Sekita T; Yoshida A; Kawai A; Ichikawa H; Kobayashi E
Genes Chromosomes Cancer; 2023 Dec; 62(12):755-760. PubMed ID: 37732625
[TBL] [Abstract] [Full Text] [Related]
12. Blast phase myeloproliferative neoplasm: contemporary review and 2024 treatment algorithm.
Tefferi A; Alkhateeb H; Gangat N
Blood Cancer J; 2023 Jul; 13(1):108. PubMed ID: 37460550
[TBL] [Abstract] [Full Text] [Related]
13. Samples from patients with AML show high concordance in detection of mutations by NGS at local institutions vs central laboratories.
Borate U; Yang F; Press R; Ruppert AS; Jones D; Caruthers S; Zhao W; Vergilio JA; Pavlick DC; Juckett L; Norris B; Bucy T; Burd A; Stein EM; Patel P; Baer MR; Stock W; Schiller G; Blum W; Kovacsovics T; Litzow M; Foran J; Heerema NA; Rosenberg L; Marcus S; Yocum A; Stefanos M; Druker B; Byrd JC; Levine RL; Mims A
Blood Adv; 2023 Oct; 7(20):6048-6054. PubMed ID: 37459200
[TBL] [Abstract] [Full Text] [Related]
14. Characteristics and prognostic impact of idh mutations in AML: a COG, SWOG, and ECOG analysis.
Zarnegar-Lumley S; Alonzo TA; Gerbing RB; Othus M; Sun Z; Ries RE; Wang J; Leonti A; Kutny MA; Ostronoff F; Radich JP; Appelbaum FR; Pogosova-Agadjanyan EL; O'Dwyer K; Tallman MS; Litzow M; Atallah E; Cooper TM; Aplenc RA; Abdel-Wahab O; Gamis AS; Luger S; Erba H; Levine R; Kolb EA; Stirewalt DL; Meshinchi S; Tarlock K
Blood Adv; 2023 Oct; 7(19):5941-5953. PubMed ID: 37267439
[TBL] [Abstract] [Full Text] [Related]
15. Mutant idh regulates glycogen metabolism from early cartilage development to malignant chondrosarcoma formation.
Pathmanapan S; Poon R; De Renshaw TB; Nadesan P; Nakagawa M; Seesankar GA; Ho Loe AK; Zhang HH; Guinovart JJ; Duran J; Newgard CB; Wunder JS; Alman BA
Cell Rep; 2023 Jun; 42(6):112578. PubMed ID: 37267108
[TBL] [Abstract] [Full Text] [Related]
16. Preclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma.
Subbiah V; Chawla SP; Conley AP; Wilky BA; Tolcher A; Lakhani NJ; Berz D; Andrianov V; Crago W; Holcomb M; Hussain A; Veldstra C; Kalabus J; O'Neill B; Senne L; Rowell E; Heidt AB; Willis KM; Eckelman BP
Clin Cancer Res; 2023 Aug; 29(16):2988-3003. PubMed ID: 37265425
[TBL] [Abstract] [Full Text] [Related]
17. Proceedings of the 2023 North American Society of Head and Neck Pathology Companion Meeting, New Orleans, LA, March 12, 2023: Navigating New Developments in High Grade Sinonasal Neuroendocrine and Neuroectodermal Neoplasms.
Rooper LM
Head Neck Pathol; 2023 Jun; 17(2):299-312. PubMed ID: 37184733
[TBL] [Abstract] [Full Text] [Related]
18. Conventional chondrosarcoma of the rib cage and sternum: clinicopathological and molecular analysis of 27 patients treated at a single institution.
Abdulfatah E; Rottmann D; Morag Y; Pantanowitz L; Udager AM; Hao W; Lucas DR
Hum Pathol; 2023 Jun; 136():63-74. PubMed ID: 37019410
[TBL] [Abstract] [Full Text] [Related]
19. Clinicopathologic Features of idh2 R172-Mutated Myeloid Neoplasms.
Davis AR; Canady BC; Aggarwal N; Bailey NG
Am J Clin Pathol; 2023 Jul; 160(1):89-97. PubMed ID: 36946516
[TBL] [Abstract] [Full Text] [Related]
20. Distinct idh1/2-associated Methylation Profile and Enrichment of
Dermawan JKT; Nafa K; Mohanty A; Xu Y; Rijo I; Casanova J; Villafania L; Benhamida J; Kelly CM; Tap WD; Boland PJ; Fabbri N; Healey JH; Ladanyi M; Lu C; Hameed M
Cancer Res Commun; 2023 Mar; 3(3):431-443. PubMed ID: 36926116
[TBL] [Abstract] [Full Text] [Related]
[Next]
